This has been performed as previously described [28 (link)]. Antibodies directed against DNMT1 (ab19905), alpha smooth muscle actin (α-SMA), Ki-67, transforming growth factor beta 1 (TGF-β1), Stromal-derived factor-1 (SDF-1), Twist-1, Vimentin (RV202), AUF1 (ab50692), N-cadherin and interleukin-6 (IL-6) were purchased from Abcam (Cambridge, MA); STAT3, pSTAT3-Tyr705 (D3A7), Snail (C15D3), E-cadherin (24E10), EpCam (UV1D9), JAK-2 (D2E12) and phospho-JAK-2 (TYR1007/1008), Cyclin D1 (2922), Akt, phospho-Akt (193H12), Nanog, NF-κB, OCT-4, PTEN, BMI-1, Lin-28B, Sox-2, ERK1/2 (137F5), phosph-ERK1/2 Glyceraldehydes-3-phosphate dehydrogenase (GAPDH, FL-335) from Cell Signaling (Danvers, MA); ZEB-1 (4C4) from Abnova (Taipei, Taiwan); p21 (F-5), p53 (DO-1), HuR (3A2), CD44 (Sp37) and CD24 (C-20) were purchased from Santa Cruz (Santa Cruz, CA), p16 (BD) was purchased from BD Biosciences (UK). Secondary antibodies are anti-Rabbit IgG HRP Conjugate (REF#W401), anti-mouse IgG HRP Conjugate (REF W402) and donkey anti-Goat IgG (H+L), HRP Conjugate (REF V805), from Promega (USA).
Free full text: Click here